Start of the clinical part of the bioequivalence study
16 February 2021
CPD has received permission from the Ministry of Health of Russia and is starting to conduct the clinical part of the bioequivalence study of a drug used in the treatment of inflammatory and degenerative diseases of the musculoskeletal system, pain syndrome from the spine (lumbago, neuralgia, myalgia, arthralgia, sciatica), a drug from the NSAID group, a derivative of phenylacetic acid.